Headlines in Dermatology Quantifying the Real-world Side Effects of FDA-approved Immunotherapy Drugs in NMSC
Headlines in Dermatology LEO’s Enstilar Performs Well in Phase 3 Study of Adults With Stable Plaque Psoriasis in China
Headlines in Dermatology Major Step Forward: FDA Clears IND Application for Vyne’s BD2-Selective BET Inhibitor